Results for tag: "Oncology Based Molecular Diagnostics"

The Oncology Based Molecular Diagnostics market intersects with the field of genomics to enhance the understanding and treatment of cancer. Molecular diagnostics involves analyzing biological markers in the genome and proteome by applying molecular biology to medical testing. In oncology, these diagnostic tools help to detect specific genetic mutations, epigenetic changes, and patterns of gene expression that are characteristic of different cancers. This information is then used for various purposes including cancer detection, prognostication, and the personalization of therapy. Advancements in genomic technologies have fostered the development of highly sensitive and specific tests capable of detecting minute amounts of cancer-related genetic material, even from circulating tumor cells or cell-free DNA. These innovations have made it possible for earlier detection, improved monitoring of treatment response, and the identification of potential therapeutic targets, thus contributing to precision medicine in oncology. Several companies operate within the Oncology Based Molecular Diagnostics market, harnessing genomic advancements to offer a range of services and products. Notable players include Illumina, Inc., known for their sequencing and array-based technologies for genomics analysis; Roche Molecular Diagnostics, part of the Roche Group, offering a variety of cancer-related diagnostic tools; Agilent Technologies, specializing in diagnostics including genomic analysis equipment and software; Thermo Fisher Scientific, which provides instruments, reagents, and software for molecular diagnostics; and Myriad Genetics, which offers predictive cancer testing and personalized medicine. These companies, among others, contribute to the development and application of molecular diagnostic technologies Show Less Read more